Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer
- PMID: 32661068
- DOI: 10.1158/1078-0432.CCR-20-1062
Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer
Abstract
Pancreatic cancer patients are in desperate need of effective therapy virtually from the moment of their diagnosis. As we acquire more therapies, how best to deploy them, in what order and to which patients is emerging as an important clinical question. Pancreatic cancer subtypes, identifiable with common lab diagnostics in diagnostic biopsy samples, may be helpful in guiding therapy selection.See related article by O'Kane et al., p. 4901.
©2020 American Association for Cancer Research.
Comment on
-
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.Clin Cancer Res. 2020 Sep 15;26(18):4901-4910. doi: 10.1158/1078-0432.CCR-19-3724. Epub 2020 Mar 10. Clin Cancer Res. 2020. PMID: 32156747